A case of omalizumab as a successful treatment for telangiectasia macularis eruptiva perstans

被引：3

作者：

Mortimore, Alexandra Maria ^{[1
]}

Barsoum, Ramez ^{[1
,2
]}

Lambie, Duncan ^{[3
]}

McMeniman, Erin ^{[1
,4
]}

机构：

[1] Princess Alexandra Hosp, Dept Dermatol, Bldg 7,Level 1,199 Ipswich Rd, Brisbane, Qld, Australia

[2] Queensland Inst Dermatol, Brisbane, Qld, Australia

[3] Princess Alexandra Hosp, Dept Pathol, Brisbane, Qld, Australia

[4] Univ Queensland, Dermatol Res Ctr, Diamantina Inst, Brisbane, Qld, Australia

来源：

AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2022年 / 63卷 / 01期

关键词：

biologic drugs; biologics; immunology; mast cell activation syndrome; mastocytosis; UNPROVOKED ANAPHYLAXIS; SYSTEMIC MASTOCYTOSIS;

D O I：

10.1111/ajd.13674

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Treatment for telangiectasia macularis eruptiva perstans (TMEP) is often challenging due to lack of an established first-line therapy and as such is primarily focused on symptomatic relief. Omalizumab shows promise as a potential therapy for mast cell disorders; however, its efficacy in TMEP is yet to be established. This case describes a 72-year-old woman with chronic refractory TMEP achieving symptomatic remission within 4 months of commencing omalizumab therapy.

引用

页码：102 / 104

页数：3

共 10 条

[1] Omalizumab-induced reductions in mast cell FcεRI expression and function
Beck, LA
Marcotte, GV
MacGlashan, D
Togias, A
Saini, S
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 114 (03) : 527 - 530
[2] Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis
Carter, Melody C.
Robyn, Jamie A.
Bressler, Peter B.
Walker, John C.
Shapiro, Gail G.
Metcalfe, Dean D.
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (06) : 1550 - 1551
[3] Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient
Douglass, J. A.
Carroll, K.
Voskamp, A.
Bourke, P.
Wei, A.
O'Hehir, R. E.
[J]. ALLERGY, 2010, 65 (07) : 926 - 927
[4] Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety
Gimenez-Arnau, Ana M.
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (03) : 375 - 385
[5] OMALIZUMAB MONOTHERAPY FOR BEE STING AND UNPROVOKED "ANAPHYLAXIS" IN A PATIENT WITH SYSTEMIC MASTOCYTOSIS AND UNDETECTABLE SPECIFIC IgE
Kontou-Fili, Kalliopi
Filis, Christos I.
Voulgari, Christina
Panayiotidis, Panayiotis G.
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2010, 104 (06) : 537 - 539
[6] Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis
Matito, Almudena
Blazquez-Goni, Cristina
Morgado, Jose M.
Alvarez-Twose, Ivan
Mollejo, Manuela
Sanchez-Munoz, Laura
Escribano, Luis
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2013, 111 (05) : 425 - 426
[7] Efficacy of Omalizumab in Indolent Systemic Mastocytosis
Slapnicar, Calum
Trinkaus, Martina
Hicks, Lisa
Vadas, Peter
[J]. CASE REPORTS IN HEMATOLOGY, 2019, 2019
[8] Omalizumab as a Desensitizing Agent and Treatment in Mastocytosis: A Review of the Literature and Case Report
Sokol, Kristin C.
Ghazi, Aasia
Kelly, Brent C.
Grant, J. Andrew
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2014, 2 (03) : 266 - 270
[9] Tharp MD, 2018, DERMATOLOGY, V4, P2102
[10] Mastocytosis - pathogenesis, clinical manifestation and treatment
Wagner, Nicola
Staubach, Petra
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 (01): : 42 - 56

← 1 →